p14ARF is capable of promoting HIV-1 tat degradation

Cell Cycle

Volumn 7, Issue 10, 2008, Pages 1433-1439

  Gargano, Barbara ^a   Fiorillo, Marianna ^a   Amente, Stefano ^b   Majello, Barbara ^a   Lania, Luigi ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Naples Oncogenomic Center (NOGEC)   (Italy)

Author keywords

Degradation; Gene expression; Inhibition; Oncosuppressor; p14ARF; Tat; Ubiquitination

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TRANSACTIVATOR PROTEIN; UBIQUITIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; COMPARATIVE STUDY; GEL CHROMATOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CHROMATOGRAPHY, GEL; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; IMMUNOPRECIPITATION; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 45749124302     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.10.5878     Document Type: Article

References (36)

1. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
2. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
3. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292-7.
4. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998; 17:5001-14.
5. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6:663-73.
6. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12:1151-64.
7. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004; 24:985-96.
8. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071-83.
9. ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001; 98:4455-60.
10. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002; 22:8398-408.
11. 1 arrest function of ARF. Mol Cell Biol 2005; 25:8024-36.
12. ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004; 431:712-7.
13. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 2004; 279:36698-707.
14. ARF Directly Interacts with Myc Through the Myc BoxII Domain. Cancer Biol Ther 2006; 5.
15. ARF interacts with N-Myc and inhibits its transcriptional activity. FEBS Lett 2007; 581:821-5.
16. ARF tumor suppressor. Genes Dev 2004; 18:830-50.
17. Suzuki H, Kurita M, Mizumoto K, Moriyama M, Aiso S, Nishimoto I, Matsuoka M. The ARF tumor suppressor inhibits BCL6-mediated transcriptional repression. Biochem Biophys Res Commun 2005; 326:242-8.
18. ARF: functional and physical link between human ARF tumor suppressor and a member of the p53 family. Mol Cell Biol 2004; 24:8529-40.
19. ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J Biol Chem 2001; 276:28421-9.
20. Barboric M, Peterlin BM. A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. PLoS Biol 2005; 3:76.
21. Bres V, Kiernan RE, Linares LK, Chable Bessia C, Plechakova O, Treand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol 2003; 5:754-61.
22. Lassot I, Latreille D, Rousset E, Sourisseau M, Linares LK, Chable-Bessia C, Coux O, Benkirane M, Kiernan RE. The proteasome regulates HIV-1 transcription by both proteolytic and nonproteolytic mechanisms. Mol Cell 2007; 25:369-83.
23. 2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 2003; 22:1822-35.
24. ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 2005; 4:597-603.
25. Tago K, Chiocca S, Sherr CJ. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc Natl Acad Sci USA 2005; 102:7689-94.
26. Puca A, Fiume G, Palmier C, Trimboli F, Olimpo F, Scala G, Quinto I. IκBα represses the transcriptional activity of the HIV-1 Tat transactivator by promoting its nuclear export. J Biol Chem 2007; 282:37146-57.
27. 2 Arrest Through ERK-Mediated Cdc25C Phosphorylation, Ubiquitination and Proteasomal Degradation. Cell Cycle 2006; 5:759-65.
28. ARF Regulates E2F-1 Ubiquitination and Degradation via a p53-Dependent Mechanism Cell Cycle 2007; 6:1741-7.
29. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. Ubiquitin-independent degradation of cell cycle inhibitors by the REGgamma proteasome. Mol Cell 2007; 26:843-52.
30. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell 2007; 26:831-42.
31. Huang X, Seifert U, Salzmann U, Henklein P, Preissner R, Henke W, Sijts AJ, Kloetzel PM, Dubiel W. The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing. J Mol Biol 2002; 323:771-82.
32. ARF inhibits the functions of the HPV16 E7 oncoprotein. Oncogene 2003; 22:5496-503.
33. Garcia MA, Collado M, Munoz Fontela C, Matheu A, Marcos-Villar L, Arroyo J, Esteban M, Serrano M, Rivas C. Antiviral action of the tumor suppressor ARF. Embo J 2006; 25:4284-92.
34. Majello B, Napolitano G, Giordano A, Lania L. Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo. Oncogene 1999; 18:4598-605.
35. Gargano B, Amente S, Majello B, Lania L. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle 2007; 6:2031-7.
36. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 2001; 414:322-5.